Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.24.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (2,681,652) $ (1,800,056)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation 650 663
Stock-based compensation 25,909 104,026
Accretion of discount and debt issuance costs on convertible notes payable 1,015,568 371,755
Changes in operating assets and liabilities:    
Inventory 28,655 3,211
Prepaid expenses and other current assets 90,067 147,492
Accounts payable 468,217 433,482
Accrued interest 171,414 152,558
Accrued expenses and other liabilities 18,567 (63,196)
Net cash used in operating activities (862,605) (650,065)
Cash flows from financing activities:    
Repayment of insurance premium financing (104,265) (106,257)
Proceeds from shareholders and third-party advances related to bridge financing 950,000 0
Proceeds from issued common stock and warrants, net of financing costs 0 20,000
Net cash provided by (used in) financing activities 845,735 (86,257)
Net decrease in cash (16,870) (736,322)
Cash, beginning of year 222,720 746,940
Cash, end of period 205,850 10,618
Conversion of Series 2 Convertible Notes and Interest Into Common Stock [Member]    
Non-cash financing activities:    
Conversion of Series 2 convertible notes and accrued interest into common stock $ 587,959 $ 0